Recently, I paid off my student loans ahead of schedule. Along with the joy of saying goodbye to 10 more years of payments, I unexpectedly felt open to doing something completely different. I stepped ...

AI rejects two-thirds of applicants before a human assessment. Professionals must work with AI and use clever tactics. Focus on business outcomes and add a human touch. Long gone are the days when ...

Canada’s new artificial intelligence strategy, AI for All, presents an ambitious vision for the country’s future. Artificial intelligence, the federal government argues, can boost productivity, ...

Lower courts can spend years interpreting the ramifications of US Supreme Court decisions that settle some constitutional matters, leave others unresolved, and never reach arguably adjacent yet ...

If dating algorithms lead romantically inclined singles to love, why not use them for electricians and welders looking for work? That was the idea behind Where Trades Go, a LinkedIn-style website ...

Trading your mortarboard for a company badge is exciting. Just make sure your first job after college is the starting point, not the high point, in a satisfying career. If you’re a new graduate, you ...

Before clean installs, dual-boot menus, and cloud everything, there was that first encounter, the moment you realized a computer wasn't just hardware, it was a system with a personality. First ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) algorithm, an ...

Gov. Gavin Newsom visited Orange County to promote his "Jobs First" program. During his visit, Newsom highlighted state investments that led to creating 61,000 jobs last year, despite a 5.5% ...

Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. Thanks ...

Teclistamab-cqyv significantly improves PFS and OS in multiple myeloma patients with 1 to 3 prior therapies, showing a 71% reduction in progression or death. The MajesTEC-9 trial highlights ...